Adherent Cells from Placenta and Use of Same in Disease Treatment
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/IB2010/003219, filed Nov 29, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,175,262 | Adherent Cells from Placenta and Use of Same in Disease Treatment In force · High confidence | Pluri Biotech Ltd. | In force | High confidence | ||
| US 10,610,545 | Adherent Cells from Placenta and Use of Same in Disease Treatment In force · High confidence | Pluri Biotech Ltd. | In force | High confidence | ||
| Application 16/749,080 | Adherent Cells from Placenta and Use of Same in Disease Treatment Abandoned Abandoned Nov 14, 2023 | Pluri Biotech Ltd. | Abandoned | Abandoned Nov 14, 2023 |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Pluri Biotech Ltd..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.